Four issues are addressed:
- Are there clinical situations in oncology where clinicians can choose between more and less expensive drugs and thus a change in the profit formula might encourage more cost-effective treatment?
- What is the total profit for doctors and hospitals for Part B drugs across their patients with varying types of insurance?
- Which drugs are favored versus disfavored by the change in the profit formula?
- How do the ‘ups’ and ‘downs’ affect the bottom line of doctors treating cancer patients? Do they end up ahead or behind?